Vivax malaria was historically described as 'benign tertian malaria'because individual
clinical episodes were less likely to cause severe illness than Plasmodium falciparum …

Malaria, a major global public health problem, is mainly caused by Plasmodium falciparum
and Plasmodium vivax, and is responsible for nearly half a million deaths annually. Although …

Background There are few published reports on severe Plasmodium vivax malaria in Africa.
Methods Clinical pattern/manifestations of severe P. vivax were described in children …

Methods: This prospective study included 539 admitted adult patients of severe malaria
(Plasmodium falciparum 274, P. vivax 221, and mixed infection of Pv+ Pf 44). The diagnosis …

Background Plasmodium vivax merozoite surface protein-1 (MSP-1) is an antigen
considered to be one of the leading malaria vaccine candidates. PvMSP-1 is highly …

Background Parenteral artesunate is the treatment of choice for severe malaria. It is safe,
efficacious and well tolerated anti-malarial. However, delayed haemolysis has been …

Objective: The study was intended to document the clinical profile and treatment outcome of
severe malaria caused by Plasmodium vivax (P. vivax) in children hospitalized in a tertiary …

Objectives Shock is a life-threatening condition in children in low-and middle-income
countries (LMIC), with several controversies. This systematic review summarizes the …

Background: In 2010, there was an increase in the severity of malaria admissions to
Kalawati Saran Children's Hospital, New Delhi and this report describes the morbidity and …

Background Thrombocytopaenia is the most frequent malaria-associated haematologic
alteration observed with all five Plasmodium parasites causing disease in humans. Although …